Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Publikationen
Suchbegriffe: OSTEOPROTEGERIN - BLOOD , . Treffer: 6
2015
Nemeth, ZK; Mardare, NG; Czira, ME; Deak, G; Kiss, I; Mathe, Z; Remport, A; Ujszaszi, A; Covic, A; Molnar, MZ; Mucsi, I
Serum osteoprotegerin is associated with pulse pressure in kidney transplant recipients.
Sci Rep. 2015; 5(1):14518-14518
Doi: 10.1038/srep14518
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2014
Todenhöfer, T; Hennenlotter, J; Leidenberger, P; Wald, A; Hohneder, A; Kühs, U; Mischinger, J; Aufderklamm, S; Gakis, G; Blumenstock, G; Stenzl, A; Schwentner, C
Serum receptor activator of nuclear factor κB ligand (RANKL) levels predict biochemical recurrence in patients undergoing radical prostatectomy.
BJU Int. 2014; 113(1):152-159
Doi: 10.1111/j.1464-410X.2012.11759.x
Web of Science
PubMed
FullText
FullText_MUG
2012
Heitzer, E; Sandner-Kiesling, A; Schippinger, W; Stohscheer, I; Osprian, I; Bitsche, S; Eisner, F; Verebes, J; Hofmann, G; Samonigg, H
IL-7, IL-18, MCP-1, MIP1-β, and OPG as biomarkers for pain treatment response in patients with cancer.
Pain Physician. 2012; 15(6):499-510
Doi: 10.36076/ppj.2012/15/499
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2010
Wagner, D; Fahrleitner-Pammer, A
Levels of osteoprotegerin (OPG) and receptor activator for nuclear factor kappa B ligand (RANKL) in serum: Are they of any help?
Wien Med Wochenschr. 2010; 160(17-18): 452-457.
Doi: 10.1007/s10354-010-0818-x
PubMed
FullText
FullText_MUG
2009
Fahrleitner-Pammer, A; Dobnig, H; Dimai, HP; Holzer, H; Benesch, T; Borchhardt, K; Cejka, D; Haas, M
The effect of RANKL and OPG on bone mineral density in pre-dialysis chronic renal failure.
Clin Nephrol. 2009; Volume 71(June): 652-659.
Doi: 10.5414/CNP71652
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
2006
Dobnig, H; Hofbauer, LC; Viereck, V; Obermayer-Pietsch, B; Fahrleitner-Pammer, A
Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients.
Osteoporos Int. 2006; 17(5):693-703
Doi: 10.1007/s00198-005-0035-4
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar